BDRX — Biodexa Pharmaceuticals Share Price
Last trade - 00:00- $0.00m
- -$1.26m
- 16
- 59
- 17
- 21
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0 | ||
| Price to Tang. Book | 0 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -94.39% | ||
| Return on Equity | -88.14% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | 0.34 | 0.58 | 0.7 | 0.38 | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company. The Company is developing a pipeline of products for the treatment of diseases with unmet medical needs. The Company’s lead development program, eRapa, is under development for familial adenomatous polyposis and non-muscle invasive bladder cancer; tolimidone, under development as a for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications, including recurrent glioblastoma, diffuse midline glioma, or DMG, and medulloblastoma. Its technologies include Q-Sphera, MidaCore and MidaSolve. The Q-Sphera platform is a polymer microsphere microtechnology used for sustained delivery to prolong and control the release of therapeutics over an extended period of time, from weeks to months. Its MidaSolve platform is an oligosaccharide nanotechnology that is used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors.
Directors
- Rolf Stahel NEC (72)
- James Phillips CEO
- Nicholas Robbins-Cherry FID (45)
- Craig Cook COO
- Daniel Palmer CSO
- Justin Barry OTH
- Tim Sparey OTH
- Simon De Vries NED (56)
- John Johnston NED
- Michele Luzi NED (57)
- Paul Protopapas NED (48)
- Simon Turton NID (47)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- September 12th, 2014
- Public Since
- December 8th, 2014
- No. of Employees
- 13
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 26,743,675.7
- Address
- 1 Caspian Point, Caspian Way, ABINGDON, CF10 4DQ
- Web
- https://www.biodexapharma.com/
- Phone
- +44 1235841575
- Auditors
- PKF Littlejohn LLP
Upcoming Events for BDRX
Similar to BDRX
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
Acurx Pharmaceuticals
NASDAQ Capital Market
FAQ
As of Today at 19:36 UTC, shares in Biodexa Pharmaceuticals are trading at $7.13. This share price information is delayed by 15 minutes.
Shares in Biodexa Pharmaceuticals last closed at $7.13 and the price had moved by -95% over the past 365 days. In terms of relative price strength the Biodexa Pharmaceuticals share price has underperformed the S&P500 Index by -95.82% over the past year.
The overall consensus recommendation for Biodexa Pharmaceuticals is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreBiodexa Pharmaceuticals does not currently pay a dividend.
Biodexa Pharmaceuticals does not currently pay a dividend.
Biodexa Pharmaceuticals does not currently pay a dividend.
To buy shares in Biodexa Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $7.13, shares in Biodexa Pharmaceuticals had a market capitalisation of $0.00m.
Here are the trading details for Biodexa Pharmaceuticals:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: BDRX
Based on an overall assessment of its quality, value and momentum Biodexa Pharmaceuticals is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Biodexa Pharmaceuticals is $180.00. That is 2424.54% above the last closing price of $7.13.
Analysts covering Biodexa Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -£1.84 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biodexa Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -83.37%.
As of the last closing price of $7.13, shares in Biodexa Pharmaceuticals were trading -74.69% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Biodexa Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $7.13.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Biodexa Pharmaceuticals' management team is headed by:
- Rolf Stahel - NEC
- James Phillips - CEO
- Nicholas Robbins-Cherry - FID
- Craig Cook - COO
- Daniel Palmer - CSO
- Justin Barry - OTH
- Tim Sparey - OTH
- Simon De Vries - NED
- John Johnston - NED
- Michele Luzi - NED
- Paul Protopapas - NED
- Simon Turton - NID